Viatris Inc. announced a definitive agreement to sell its equity stake in Biocon Biologics Limited to Biocon Limited for $815 million. The deal, comprised of $400 million in cash and $415 million in newly issued equity shares of Biocon, will accelerate the expiration of biosimilars non-compete restrictions for Viatris. The transaction is expected to finalize in the first quarter of 2026.

VTRS

<p>Viatris Inc. announced a definitive agreement to sell its equity stake in Biocon Biologics Limited to Biocon Limited for $815 million. The deal, comprised of $400 million in cash and $415 million in newly issued equity shares of Biocon, will accelerate the expiration of biosimilars non-compete restrictions for Viatris. The transaction is expected to finalize in the first quarter of 2026.</p>

Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln